Sign inJoin waitlistJoin the waitlist

Scott Gettinger

Associate Program Director · Yale-New Haven Hospital

Credentials: · · ·

History

Yale-New Haven Hospital
Present
Thoracic Medical Oncology Division · Yale-New Haven Hospital
Present
Thoracic Medical Oncology Division · Yale School of Medicine
Present

Yale University
2005–2007
Beth Israel Medical Center
2004–2005
Beth Israel Medical Center-North Division
1999–2002
Renaissance School of Medicine at Stony Brook University
1995–1999
Brooklyn College
1991–1995
Trinity College
1991

Research

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
New England Journal of Medicine · 2012 · 10,404 citations
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
New England Journal of Medicine · 2015 · 7,953 citations
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Nature · 2014 · 4,371 citations

RH
Roy Herbst
27 papers
Sarah Goldberg
17 papers · 1 as a fellow
LH
Leora Horn
16 papers
GR
Gregory Riely
15 papers
Scott Antonia
15 papers
DR
David Rimm
14 papers
Julie Brahmer
14 papers
Ross Camidge
14 papers
DS
David Spigel
13 papers
KS
Kurt Schalper
13 papers
Michael Lanuti
12 papers
Alda Tam
11 papers

Clinical trials

The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer
Principal investigator · Active not recruiting · Phase 2
Yale University
2021–2026
Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.
Principal investigator · Completed · Phase 2
Yale University
2017–2022
Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer
Principal investigator · Withdrawn · Phase 2
Yale University
2015–2017
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Site PI · Recruiting · Phase 1
SystImmune Inc.
2023–2030